Core Viewpoint - Merck is set to report its third-quarter 2025 earnings on October 30, with consensus estimates for sales at $17.06 billion and earnings per share (EPS) at $2.36. Earnings estimates for 2025 have slightly declined from $8.94 to $8.92 per share over the past month [1][6]. Earnings Performance - Merck has consistently exceeded earnings expectations in the last four quarters, with an average earnings surprise of 3.92%. The most recent quarter showed a 5.97% surprise [3][4]. Factors Influencing Upcoming Results - After a weak first half, Merck anticipates growth in the second half, driven by oncology drugs like Keytruda, Animal Health, and new products, although this may be partially offset by lower sales of Gardasil in China and Japan [6][7]. Oncology Drug Performance - Keytruda is expected to drive significant sales growth, with consensus estimates for its sales at $8.4 billion, while internal estimates are slightly higher at $8.51 billion. The drug's sales are bolstered by its uptake in earlier-stage indications and continued momentum in metastatic indications [8][9]. Vaccine and Other Drug Performance - Sales of Gardasil are projected to decline due to reduced demand in China and Japan, with consensus estimates at $1.75 billion, while internal estimates are at $1.70 billion. Other vaccines have also seen declining sales [11][12]. - The diabetes franchise is facing challenges from lower demand and generic competition, impacting sales of Januvia/Janumet [14]. New Product Contributions - New drugs like Winrevair and Capvaxive are contributing to sales growth, with Winrevair showing strong demand in the U.S. market and Capvaxive gaining traction in retail pharmacies [15][24]. Financial Performance and Valuation - Merck's stock has underperformed the industry and the S&P 500, with a year-to-date loss of 11.5% compared to a 5.7% increase for the industry. However, the company's valuation appears attractive, trading at a forward P/E ratio of 9.42, lower than the industry average of 15.58 [17][20]. Investment Thesis - Merck has a robust portfolio with over six blockbuster drugs, primarily driven by Keytruda. The company has also expanded its pipeline significantly, with plans to launch around 20 new vaccines and drugs in the coming years [23][24]. - Despite concerns about dependency on Keytruda and challenges in the non-oncology business, Merck's strong revenue generation from its existing products supports a long-term investment perspective [26][29].

Core Viewpoint - Jack Henry (JKHY) is anticipated to report a year-over-year increase in earnings driven by higher revenues for the quarter ended September 2025, with the actual results being crucial for its near-term stock price movement [1][2]. Earnings Expectations - The upcoming earnings report is expected to be released on November 4, with a consensus estimate of quarterly earnings at $1.64 per share, reflecting a year-over-year change of +0.6%. Revenues are projected to be $636.69 million, an increase of 5.9% from the previous year [3]. Estimate Revisions - Over the last 30 days, the consensus EPS estimate has been revised down by 0.87%, indicating a reassessment by analysts regarding the company's earnings prospects [4]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that the Most Accurate Estimate for Jack Henry is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -6.42%, suggesting a bearish outlook from analysts [12]. Historical Performance - In the last reported quarter, Jack Henry exceeded the expected earnings of $1.46 per share by delivering $1.75, resulting in a surprise of +19.86%. The company has beaten consensus EPS estimates in the last four quarters [13][14]. Investment Considerations - Despite the potential for an earnings beat, the combination of a negative Earnings ESP and a Zacks Rank of 3 makes it challenging to predict a positive outcome for the upcoming earnings report [12][17].

Core Viewpoint - Wall Street anticipates a year-over-year increase in earnings for PTC Therapeutics despite lower revenues, with actual results being crucial for stock price movement [1][2]. Earnings Expectations - The earnings report is set to be released on November 4, with expectations of a quarterly loss of $1.19 per share, reflecting a year-over-year change of +14.4%. Revenues are projected at $175.6 million, down 10.8% from the previous year [3][2]. Estimate Revisions - The consensus EPS estimate has been revised 12.37% higher in the last 30 days, indicating a collective reassessment by analysts [4]. Earnings Surprise Prediction - The Zacks Earnings ESP model shows a positive Earnings ESP of +5.75% for PTC Therapeutics, suggesting a likelihood of beating the consensus EPS estimate [12]. Historical Performance - PTC Therapeutics has a history of beating consensus EPS estimates, having done so in the last four quarters, including a +22.43% surprise in the last reported quarter [13][14]. Additional Considerations - While an earnings beat may influence stock movement, other factors can also play a significant role in determining stock performance post-earnings release [15][17].

Company Overview - Ultragenyx (RARE) is expected to report a year-over-year increase in earnings driven by higher revenues for the quarter ended September 2025, with a consensus outlook indicating a quarterly loss of $1.23 per share, reflecting a +12.1% change from the previous year [1][3] - Revenues are anticipated to reach $167.55 million, representing a 20.1% increase compared to the same quarter last year [3] Earnings Estimates and Revisions - The consensus EPS estimate has been revised 0.43% lower over the last 30 days, indicating a reassessment by analysts regarding the company's earnings prospects [4] - The Most Accurate Estimate for Ultragenyx is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -12.47%, suggesting a bearish outlook from analysts [12] Earnings Surprise History - In the last reported quarter, Ultragenyx was expected to post a loss of $1.27 per share but actually reported a loss of -$1.17, achieving a surprise of +7.87% [13] - Over the past four quarters, the company has beaten consensus EPS estimates two times [14] Industry Context - In the Zacks Medical - Biomedical and Genetics industry, Vertex Pharmaceuticals (VRTX) is expected to report earnings of $4.55 per share for the same quarter, indicating a year-over-year change of +3.9% and revenues of $3.04 billion, up 9.7% from the previous year [18][19] - Vertex has an Earnings ESP of +0.57% and a Zacks Rank of 3, suggesting a likelihood of beating the consensus EPS estimate [19][20]

Core Viewpoint - uniQure (QURE) is anticipated to report a year-over-year increase in earnings driven by higher revenues in its upcoming quarterly results for September 2025 [1] Financial Expectations - The consensus estimate indicates a quarterly loss of $0.85 per share, reflecting a year-over-year change of +6.6% [3] - Expected revenues are projected at $6.93 million, representing a significant increase of 202.6% from the same quarter last year [3] Estimate Revisions - The consensus EPS estimate has been revised 4.79% higher in the last 30 days, indicating a positive reassessment by analysts [4] - The Most Accurate Estimate for uniQure is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +22.54% [12] Earnings Surprise Potential - A positive Earnings ESP reading suggests a strong likelihood of an earnings beat, especially when combined with a Zacks Rank of 3 [10][12] - Historically, uniQure has beaten consensus EPS estimates three out of the last four quarters, with a notable surprise of +22.47% in the last reported quarter [13][14] Industry Context - In comparison, Axsome Therapeutics (AXSM) is expected to report a loss of $0.85 per share for the same quarter, with revenues projected at $164.05 million, up 56.6% year-over-year [18][19] - Axsome's consensus EPS estimate has been revised 38.2% lower recently, resulting in a negative Earnings ESP of -14.93% [19][20]

Core Insights - Rhythm Pharmaceuticals, Inc. (RYTM) is expected to report a year-over-year increase in earnings driven by higher revenues for the quarter ended September 2025, with a consensus outlook indicating a quarterly loss of $0.72 per share, reflecting a +1.4% change from the previous year, and revenues projected at $50.24 million, up 51.1% from the year-ago quarter [1][3] Earnings Expectations - The earnings report is anticipated to be released on November 4, and if the actual results exceed expectations, the stock may experience upward movement; conversely, a miss could lead to a decline [2] - The consensus EPS estimate has remained unchanged over the last 30 days, indicating stability in analyst expectations [4] Earnings Surprise Prediction - The Zacks Earnings ESP model suggests that the Most Accurate Estimate for Rhythm Pharmaceuticals is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +9.24%, indicating a bullish sentiment among analysts [11] - A positive Earnings ESP is a strong predictor of an earnings beat, especially when combined with a Zacks Rank of 1 (Strong Buy), 2 (Buy), or 3 (Hold) [9] Historical Performance - In the last reported quarter, Rhythm Pharmaceuticals was expected to post a loss of $0.66 per share but actually reported a loss of -$0.75, resulting in a surprise of -13.64% [12] - Over the past four quarters, the company has only beaten consensus EPS estimates once [13] Conclusion - Rhythm Pharmaceuticals is viewed as a compelling candidate for an earnings beat, but investors should consider other factors influencing stock performance beyond just earnings results [16]

Core Viewpoint - The market anticipates a year-over-year decline in Leidos' earnings despite an increase in revenues for the quarter ending September 2025, with actual results being crucial for stock price movement [1][2]. Earnings Expectations - Leidos is expected to report earnings of $2.61 per share, reflecting a year-over-year decrease of 10.9%, while revenues are projected to be $4.27 billion, an increase of 1.8% from the previous year [3]. Estimate Revisions - The consensus EPS estimate has been revised 0.26% higher in the last 30 days, indicating a slight positive reassessment by analysts [4]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that the Most Accurate Estimate for Leidos is lower than the consensus estimate, resulting in an Earnings ESP of -2.30%, suggesting a bearish outlook from analysts [12]. Historical Performance - Leidos has consistently beaten consensus EPS estimates in the past four quarters, with a notable surprise of +22.05% in the last reported quarter [13][14]. Investment Considerations - Despite the historical performance, the current combination of a negative Earnings ESP and a Zacks Rank of 3 makes it challenging to predict an earnings beat for Leidos [12][17].

Core Viewpoint - The market anticipates a year-over-year decline in earnings for LGI Homes due to lower revenues, with a focus on how actual results compare to estimates impacting stock price [1][2]. Earnings Expectations - LGI Homes is expected to report quarterly earnings of $1.02 per share, reflecting a year-over-year decrease of 65.4%, with revenues projected at $416.73 million, down 36.1% from the previous year [3]. - The consensus EPS estimate has been revised down by 9.77% over the last 30 days, indicating a reassessment by analysts [4]. Earnings Surprise Prediction - The Zacks Earnings ESP model suggests that the Most Accurate Estimate for LGI Homes is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -5.21% [12]. - The stock currently holds a Zacks Rank of 5, indicating a bearish outlook, making it challenging to predict an earnings beat [12]. Historical Performance - In the last reported quarter, LGI Homes exceeded expectations by delivering earnings of $1.36 per share against an expected $1.21, resulting in a surprise of +12.40% [13]. - Over the past four quarters, the company has beaten consensus EPS estimates twice [14]. Conclusion - LGI Homes does not appear to be a strong candidate for an earnings beat, and investors should consider additional factors when evaluating the stock ahead of the earnings release [17].

Core Insights - Wall Street anticipates a year-over-year increase in earnings for Madrigal (MDGL) due to higher revenues, with a focus on how actual results compare to estimates [1][2] - The upcoming earnings report is expected to be released on November 4, and stock movement will depend on whether key numbers exceed or fall short of expectations [2] Financial Expectations - Madrigal is projected to report a quarterly loss of $1.99 per share, reflecting a year-over-year change of +59.6% [3] - Revenues are expected to reach $249.15 million, representing a significant increase of 300.8% from the same quarter last year [3] Estimate Revisions - The consensus EPS estimate has been revised 10.44% higher in the last 30 days, indicating a positive reassessment by analysts [4] - The Most Accurate Estimate for Madrigal is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +27.84% [12] Earnings Surprise Prediction - A positive Earnings ESP reading suggests a likely earnings beat, especially when combined with a Zacks Rank of 2 (Buy) [10][12] - Madrigal has a history of beating consensus EPS estimates, having done so in the last four quarters [14] Industry Context - Another company in the Zacks Medical - Drugs industry, BioCryst Pharmaceuticals (BCRX), is expected to post earnings of $0.07 per share, indicating a year-over-year change of +200% [18] - BioCryst's revenues are projected to be $161.15 million, up 37.6% from the previous year, with an Earnings ESP of +17.12% [19][20]

Core Viewpoint - Oportun Financial Corporation (OPRT) is expected to report a year-over-year increase in earnings despite lower revenues for the quarter ended September 2025, with the actual results being crucial for stock price movement [1][2]. Earnings Expectations - The consensus estimate for Oportun Financial's quarterly earnings is $0.26 per share, reflecting a significant year-over-year increase of +1200% [3]. - Revenues are projected to be $238.85 million, which is a decrease of 4.5% compared to the same quarter last year [3]. Estimate Revisions - Over the last 30 days, the consensus EPS estimate has been revised 3% lower, indicating a reassessment by analysts regarding the company's earnings prospects [4]. - The Most Accurate Estimate for Oportun Financial is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -13.73%, suggesting a bearish outlook from analysts [12]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that a positive or negative reading can predict the likelihood of actual earnings deviating from consensus estimates, with a positive reading being a strong predictor of an earnings beat [9][10]. - Oportun Financial currently holds a Zacks Rank of 3 (Hold), complicating predictions regarding an earnings beat [12]. Historical Performance - In the last reported quarter, Oportun Financial exceeded the expected earnings of $0.22 per share by delivering $0.31, resulting in a surprise of +40.91% [13]. - Over the past four quarters, the company has beaten consensus EPS estimates three times [14]. Industry Comparison - Acadian Asset Management (AAMI), another player in the Zacks Financial - Miscellaneous Services industry, is expected to report earnings of $0.73 per share for the same quarter, representing a year-over-year change of +23.7% [18]. - AAMI's revenues are anticipated to be $145.62 million, up 18.3% from the previous year, with a recent EPS estimate revision of +5.1% [19].